Explore the research behind each compound.
Editorial evidence groups, not rankings of effectiveness, safety or suitability. Research vials do not inherit medicine approval.
Showing 26 of 26 published compounds
Studied in people
5 compoundsAlso known as PT-141. Human trials studied a specific sexual desire disorder in premenopausal women.
Catalog record updated 31 Oct 2026.
2019 · Human randomized trialBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsA human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
A long-acting growth hormone-releasing hormone analogue studied through early human hormone measurements.
Catalog record updated 31 Oct 2026.
2006 · Human early-phase trialProlonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adultsA human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
A GIP, GLP-1, and glucagon receptor agonist evaluated in the linked phase 2 obesity trial.
Catalog record updated 31 Oct 2026.
2023 · Human randomized trialTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial2022 · Human randomized trialLY3437943, a triple receptor agonist: a phase 1b trial in people with type 2 diabetesA human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
A GHRH analogue with human studies in HIV-associated abdominal fat accumulation. Findings are specific to the studied population.
Catalog record updated 31 Oct 2026.
2014 · Human randomized trialEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulationA human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
A GIP and GLP-1 receptor agonist evaluated in large randomized human studies of metabolic disease.
Catalog record updated 31 Oct 2026.
2022 · Human randomized trialTirzepatide Once Weekly for the Treatment of ObesityA human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
Early biological signals
4 compoundsAn experimental 15-amino-acid peptide studied in tissue-injury models. Animal findings require careful separation from human evidence.
Catalog record updated 31 Oct 2026.
2003 · Animal & cell studyGastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growthA result in a laboratory or animal model cannot establish that the same effect occurs in people.
A copper-bound tripeptide investigated in laboratory models of skin and extracellular matrix biology.
Catalog record updated 31 Oct 2026.
2007 · In-vitro studyIn vitro observations on the influence of copper peptide aids for the LED photoirradiation of fibroblast collagen synthesisA result in a laboratory or animal model cannot establish that the same effect occurs in people.
A growth hormone secretagogue characterized in preclinical pharmacology studies.
Catalog record updated 31 Oct 2026.
1998 · Animal & cell studyIpamorelin, the first selective growth hormone secretagogueA result in a laboratory or animal model cannot establish that the same effect occurs in people.
A 16-amino-acid mitochondrial-derived peptide studied in cell signaling and mouse metabolism.
Catalog record updated 31 Oct 2026.
2015 · Animal & cell studyThe mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceA result in a laboratory or animal model cannot establish that the same effect occurs in people.
Questions remain open
17 compoundsA non-peptide research small molecule. It belongs in a related-compounds category rather than being labeled a peptide.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A growth-hormone-fragment-related research compound. Advertising claims do not establish treatment efficacy.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A peptide in metabolic and appetite-signaling research. The complete trial review is pending in this catalog.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
Delta sleep-inducing peptide, also called emideltide. Its name alone does not demonstrate a sleep benefit.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
An experimental cellular research compound. Longevity and anti-aging claims need substantially stronger clinical evidence.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
An endogenous tripeptide involved in redox biology. It should not be grouped with unrelated “detox” claims.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A modified IGF-I research material. It is distinct from licensed recombinant human IGF-I medicines.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A family of peptides investigated in reproductive hormone signaling. Sequence length and experimental context matter.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A short peptide included in experimental inflammatory research. This catalog has not established human treatment efficacy.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A host-defense peptide in experimental immune research. Biological activity does not imply safe administration.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
Nicotinamide adenine dinucleotide is a coenzyme, not a peptide. Endogenous biochemical roles do not establish an injectable wellness benefit.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A neuropeptide research topic with important evidence and safety gaps for products marketed online.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
An experimental neuropeptide topic. Evidence needs evaluation by exact formulation, study design, and population.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A peptide associated with growth hormone-releasing hormone research. A full evidence review is pending.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
Also known as elamipretide, a compound researched in mitochondrial biology. Indications and product status require product-specific verification.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A research name used for thymosin beta-4-related materials. Exact sequence and formulation must be established before comparing studies.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
A peptide included in immune research. This catalog has not completed a product- or indication-specific evidence review.
Catalog record updated 31 Oct 2026.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
The group comes directly from the compound’s editorial evidence label.
The catalog identifies a medicine with a specific approved use. The indication, formulation, population and jurisdiction still matter.
An approval for a licensed medicine does not transfer to a Peptoryn research vial or to a different use.
The curated record describes human research. Trial phase, participants, outcomes and follow-up determine what that research can support.
A human study can be small or exploratory. It does not by itself establish approval, lasting benefit or safety.
The catalog is grounded mainly in cell or animal research. These studies explore mechanisms and generate questions for human trials.
A result in a laboratory or animal model cannot establish that the same effect occurs in people.
The curated record has limited, sparse or indirect evidence for the claims commonly associated with the compound.
Limited evidence means uncertainty. It is neither proof of benefit nor proof that a compound has no effect.
This is an editorial snapshot of Peptoryn’s published catalog, not a systematic review or a live assessment of global regulatory status. Records can include selected studies rather than the full literature. Record dates show the last catalog edit, not a new clinical or regulatory review. Molecules within a group appear alphabetically; there is no ranking within a tier.
Read the research vault